Catalyst
Slingshot members are tracking this event:
Mylan (MYL) and Biocon Submit Biologics License Application (BLA) to FDA for Biosimilar to Roche's (RHHBY) Herceptin for HER2-Positive Breast and Gastric Cancers
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MYL |
|
|
RHHBY |
|
|
Biocon Ltd. |
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 08, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Biologics License Application, Bla, Fda, Biosimilar, Herceptin, Her2-positive Breast Cancer, Gastric Cancers
